Champions Biotechnology is in a unique position to identify high potential drug candidates, particularly those that target new cancer pathways. Champions intends to utilize its preclinical platform and predictive tumor specific data to identify chemotherapeutic candidates with the greatest potential.

The Company’s preclinical platform may enable the discovery of biomarkers for such drugs and the development of companion diagnostic tests to identify the specific patients that are most likely to benefit from the drug. Such methodology may be employed for clinical trial patient selection to enhance the likelihood that primary endpoints are effectively achieved.

The Company plans to acquire or partner to develop a portfolio of new chemotherapeutic drug candidates through pre-clinical trials. If drug candidates successfully reach the completion of preclinical development, the Company intends to sell, license or partner with pharmaceutical and/or biotechnology companies, as appropriate. We anticipate that this plan will enable the Company to maximize its return on investment in a relatively short time frame.

Champions Biotechnology has already acquired the patent rights for two Benzoylphenylurea (BPU) sulfur analog compounds (SG410 and SG430) with promising in vivo and in vitro activity against prostate and pancreatic cancer. The acquired rights include pending U.S. Patent Application and the corresponding international patent application filed under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs. These compounds are antimiotic inhibitors that were shown in a Tumorgraft model to target microtubule associated protein tau (MAPT) deficient tumors with promising results as compared to a currently marketed and leading chemotherapeutic drug.

For additional information see Journal of Medicinal Chemistry, 2006, Vol. 49, No.7, 2357-2360 and American Association for Cancer Research Journal of Molecular Cancer Therapeutics, Vol. 6, Issue 5, May 2007, 1509-16.